RLYB

Rallybio Corp (RLYB) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Rallybio Corp is a clinical-stage biotechnology company focused on developing therapies for rare diseases, primarily its lead candidate RLYB116 (a C5 inhibitor). The company is currently in the process of a proposed merger with Avenzo Therapeutics, Inc., which, if completed, will result in Rallybio changing its name to Avenzo Therapeutics, Inc. and Rallybio shareholders owning approximately 2.8% of the combined entity.

Key Financial Metrics

Material Changes vs. Prior Period

• Termination Fee Impact: The primary driver of the net income turnaround was a $50.0 million termination fee received on May 4, 2026, following the termination of a proposed merger with Candid Therapeutics, Inc. This resulted in a $50.0 million increase in "Total other income, net."
• Revenue Decline: Collaboration and license revenue dropped to zero in Q2 2026 as the two-year collaboration agreement with Johnson & Johnson (J&J) expired in April 2026. All revenue obligations under that agreement were satisfied.
• Expense Reduction: Operating expenses decreased significantly. Research and Development (R&D) expenses fell from $6.1 million in Q2 2025 to $0.8 million in Q2 2026. This reduction is attributed to the discontinuation of the RLYB212 program in April 2025 and a reduction in headcount.
• Liquidity Improvement: Cash and cash equivalents increased from $31.4 million at year-end 2025 to $92.8 million at June 30, 2026, driven by the termination fee and proceeds from the maturity of marketable securities.

Guidance, Outlook, and Risks

• Merger with Avenzo: On May 31, 2026, Rallybio entered into a definitive merger agreement with Avenzo Therapeutics. The transaction is expected to close prior to the end of 2026. Upon closing, Rallybio shareholders will receive Contingent Value Rights (CVRs) entitling them to a pro-rata share of proceeds from the sale of Rallybio's legacy assets (including RLYB116) and future payments from Recursion Pharmaceuticals.
• Capital Requirements: Management expects current cash ($92.8 million) to fund operations for more than 12 months. However, the company anticipates the merger will close before this runway is exhausted. If the merger fails, the company will require significant additional capital to continue development.
• Program Status:
  • RLYB116: Lead program in early-stage clinical development. A confirmatory PK/PD study was completed in 2025 with data reported in Q1 2026 showing improved tolerability and sustained complement inhibition.
  • RLYB212: Discontinued in April 2025 due to failure to achieve target concentrations in Phase 2 trials.
  • REV102: Sold to Recursion Pharmaceuticals in July 2025; Rallybio retains rights to future milestones and royalties.
• Risks: Key risks include the failure to consummate the Avenzo merger, the uncertainty of CVR payments, the high risk of clinical failure for RLYB116, and the need for additional financing if the merger does not close.

Investor Verification Checklist

• Merger Closing Conditions: Verify the status of regulatory approvals and shareholder votes required to close the Avenzo merger.
• CVR Valuation: Assess the likelihood and timing of future payments from the sale of legacy assets (RLYB116) and Recursion milestones, which determine the value of the Contingent Value Rights.
• Cash Runway: Confirm the burn rate post-merger announcement and the sufficiency of the $92.8 million cash balance to sustain operations until closing or a new financing event.
• RLYB116 Development: Monitor upcoming clinical trial data and regulatory interactions for the lead asset, as its success is critical for the CVR value.
• Stock Dilution: Review the pro forma capitalization, noting that pre-merger Rallybio shareholders are expected to own only ~2.8% of the combined company.